Forecast

The analysts' average price target is €77.96 (+60.12%). The median is €76.96 (+58.06%).

Buy	19
Hold	14
Sell	0

News Go to news feed

Ionis Pharmaceuticals falls sharply after Pelacarsen trial failure

Ionis Pharmaceuticals' stock fell about 13% premarket after the Phase‑3 Lp(a)HORIZON trial of Pelacarsen, developed with Novartis, failed. Although Pelacarsen lowered Lipoprotein(a) levels, it did not significantly reduce the combined risk of cardiovascular death, heart attack, stroke or urgent revascularization. As a result, expected future licensing and milestone payments to Ionis will likely not materialize and the stock is approaching its 52‑week low; analysts say the downside is partly limited by the rest of the pipeline and recent approvals. » More on de.investing.com
Ionis Pharmaceuticals receives early FDA approval for Zanvastro and sees significant upside potential

The FDA approved Zanvastro 19 days ahead of the PDUFA date, opening an unserved market for a rare neurological disease. H.C. Wainwright reiterates a buy rating with a $115 price target, implying roughly 98% upside. The potential sale of a Priority Review Voucher for about $200 million would strengthen the financial base for further development. » More on finanzen.net
Strong quarterly results drive Ionis Pharmaceuticals stock higher premarket

Ionis Pharmaceuticals reported a loss per share of $0.69 and revenue of $268 million in the second quarter, with both metrics comfortably beating consensus expectations. The results point to faster‑than‑expected sales for Tryngolza (Olezarsen), despite a substantial price cut ahead of broader approval. After the stock plunged following the failure of the Phase‑3 CARDIO‑TTRansform study, the premarket recovery now reflects the solid commercial numbers and positive analyst commentary, with an average 12‑month price target of about $92.95. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2000, Ionis Pharmaceut has already paid €0.67 in dividends. The last payout was in May 2000.

Financials

In the last quarter, Ionis Pharmaceut had revenue of €234.78M and net profit of -€100.45M

(EUR)	June 2026	YoY
Revenue	234.78M	38.78%
Gross profit	232.38M	38.85%
Net profit	-100.45M	195.83%
EBITDA	-92.29M	172.41%

Fundamentals

Metric	Value
Market capitalization	€8.3B
Number of shares	166.18M
52-week high/low	€74.59 - €43.00
Dividends	No
Beta	0.42
P/E ratio	-16.79
PEG ratio	0.20
P/B ratio	21.85
P/S ratio	11.05

Company profile

Ionis Pharmaceuticals, Inc. erforscht und entwickelt in den Vereinigten Staaten RNA-gezielte Therapeutika. Das Unternehmen bietet SPINRAZA für spinale Muskelatrophie (SMA) bei pädiatrischen und erwachsenen Patienten, TEGSEDI, eine Injektion zur Behandlung der Polyneuropathie der hereditären Transthyretin-vermittelten Amyloidose bei Erwachsenen, und WAYLIVRA, eine Behandlung für das familiäre Chylomikronämie-Syndrom und die familiäre partielle Lipodystrophie. Darüber hinaus entwickelt das Unternehmen Medikamente für verschiedene Indikationen, die sich in Phase-3-Studien befinden, darunter Eplontersen als monatliche subkutane Injektion zur Selbstverabreichung zur Behandlung aller Arten von TTR-Amyloidose; Olezarsen für Patienten mit schwerer Hypertriglyceridämie (SHTG); Donidalorsen für Patienten mit hereditärem Angioödem; ION363 für Patienten mit amyotropher Lateralsklerose; Pelacarsen für Patienten mit etablierten Herz-Kreislauf-Erkrankungen und erhöhtem Lipoprotein(a); und Tofersen zur Hemmung der Produktion von Superoxid-Dismutase 1. Darüber hinaus entwickelt das Unternehmen Medikamente für Stoffwechselkrankheiten, Infektionskrankheiten, Nierenkrankheiten, Augenkrankheiten und Krebs. Es unterhält eine strategische Zusammenarbeit mit Biogen Inc. sowie Kooperations- und Lizenzvereinbarungen mit AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc. und Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. wurde 1989 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.

Name	Ionis Pharmaceut
CEO	Brett Monia
Headquarters	Carlsbad, ca USA
Website	ionispharma.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	05/17/1991
Employees	1,480